Groupe d'Etude en Oncologie du Quebec

Titre	A Multi-Country, Real-World Study to Explore Treatment Patterns, Effectiveness and Healthcare Resource Utilization for Patients Diagnosed With Myelofibrosis Through Chart Review
Protocole ID	METER
ClinicalTrials.gov ID	NCT05444972
Type(s) de cancer	NMP : Vaquez , Thrombocythémie essentielle, Métaplasie myéloide
Phase	Autres
Type étude	Autre
Institution	CIUSSS DE L'EST-DE-L'ILE-DE-MONTREAL PAV. MAISONNEUVE/PAV. MARCEL-LAMOUREUX 5415 boul. de l'Assomption, Montréal, QC, H1T2M4
Ville	Montréal
Investigateur(trice) principal(e)	Dre Natasha Szuber
Coordonnateur(trice)
Statut	Actif en recrutement
Date d'activation	16-11-2022
Critètes d'éligibilité	Treated for myelofibrosis (MF) [primary myelofibrosis (PMF) and secondary myelofibrosis (SMF)]. Must have initiated their first treatment on or after the first date when ruxolitinib was approved in their country of residence and no later than 31 December 2021.
Critètes d'exclusion	Having received MF treatment in a clinical trial setting.

Groupe d'étude en oncologie du Québec